Collegium Ends Grünenthal Nucynta U.S. License in $17 Million Settlement
Collegium Pharmaceutical and Grünenthal settled disputes related to Nucynta, including pending patent litigation over the authorized generic for Nucynta ER. They mutually terminated their 2015 U.S. License Agreement.
Collegium Pharmaceutical reached a settlement with Grünenthal on Oct 15, 2026 to resolve all disputes related to Nucynta, including pending patent litigation over the authorized generic for Nucynta ER. As part of the deal, the parties mutually terminated the 2015 U.S. License Agreement and ended th…